Mandate

Vinge advises Stendörren in connection with issuance of green capital securities and tender offer

May 17, 2024 Banking and Finance

Vinge has advised Stendörren Fastigheter AB in connection with its issuance of green subordinated and perpetual capital securities in an amount of SEK 300 million (within a framework of SEK 400 million) and its parallel tender offer in respect of its previously issued capital securities.

The capital securities were issued with a coupon of STIBOR 3m + 550 basis points until the first ordinary call date, and they are intended to be listed on the sustainable bond list of Nasdaq Stockholm. An amount equivalent to the net proceeds from the issuance will be applied in accordance with Stendörren’s green finance framework and towards the repurchase of its outstanding capital securities. Stendörren has received tenders in a total nominal amount of SEK 132,500,000 and intends to accept all tenders received.

Skandinaviska Enskilda Banken AB (publ) and Swedbank AB (publ) acted as arrangers and joint bookrunners in connection with the issuance of the green capital securities, and as dealer managers in connection with the tender offer.

Vinge’s team consisted of Mikael Ståhl, Lionardo Ojeda and Calle Tengwall Pagels.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026